Design, analysis, and interpretation of treatment response heterogeneity in personalized nutrition and obesity treatment research.
heterogeneity of treatment effect
personalized medicine
personalized nutrition
tailored treatment
Journal
Obesity reviews : an official journal of the International Association for the Study of Obesity
ISSN: 1467-789X
Titre abrégé: Obes Rev
Pays: England
ID NLM: 100897395
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
29
03
2023
received:
02
07
2022
accepted:
24
07
2023
medline:
22
11
2023
pubmed:
5
9
2023
entrez:
5
9
2023
Statut:
ppublish
Résumé
It is increasingly assumed that there is no one-size-fits-all approach to dietary recommendations for the management and treatment of chronic diseases such as obesity. This phenomenon that not all individuals respond uniformly to a given treatment has become an area of research interest given the rise of personalized and precision medicine. To conduct, interpret, and disseminate this research rigorously and with scientific accuracy, however, requires an understanding of treatment response heterogeneity. Here, we define treatment response heterogeneity as it relates to clinical trials, provide statistical guidance for measuring treatment response heterogeneity, and highlight study designs that can quantify treatment response heterogeneity in nutrition and obesity research. Our goal is to educate nutrition and obesity researchers in how to correctly identify and consider treatment response heterogeneity when analyzing data and interpreting results, leading to rigorous and accurate advancements in the field of personalized medicine.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13635Subventions
Organisme : NIH HHS
ID : R25DK099080
Pays : United States
Organisme : NIH HHS
ID : P30AG050886
Pays : United States
Organisme : NIH HHS
ID : U24AG056053
Pays : United States
Organisme : NIH HHS
ID : R25HL124208
Pays : United States
Organisme : NIA NIH HHS
ID : 3R01AG057703-02S1
Pays : United States
Organisme : NCI NIH HHS
ID : U01-CA057030-29S1
Pays : United States
Organisme : NIH HHS
ID : R25DK099080
Pays : United States
Organisme : NIH HHS
ID : P30AG050886
Pays : United States
Organisme : NIH HHS
ID : U24AG056053
Pays : United States
Organisme : NIH HHS
ID : R25HL124208
Pays : United States
Organisme : NIA NIH HHS
ID : 3R01AG057703-02S1
Pays : United States
Organisme : NCI NIH HHS
ID : U01-CA057030-29S1
Pays : United States
Informations de copyright
© 2023 The Authors. Obesity Reviews published by John Wiley & Sons Ltd on behalf of World Obesity Federation.
Références
Kaiser KA, Gadbury GL. Estimating the range of obesity treatment response variability in humans: methods and illustrations. Hum Hered. 2013;75(2-4):127-135. doi:10.1159/000351738
Adams SH, Anthony JC, Carvajal R, et al. Perspective: guiding principles for the implementation of personalized nutrition approaches that benefit health and function. Adv Nutr. 2020;11(1):25-34. doi:10.1093/advances/nmz086
US Food and Drug Administration. in Public Workshop on Patient-Focused Drug Development: Guidance 4-Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision Making. Silver Spring; 2019.
Senn S. Mastering variation: variance components and personalised medicine. Stat Med. 2016;35(7):966-977. doi:10.1002/sim.6739
Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. J Educ Psychol. 1974;66(5):688-701. doi:10.1037/h0037350
Senn S. Statistical pitfalls of personalized medicine. Nature. 2018;563(7733):619-621. doi:10.1038/d41586-018-07535-2
Williamson PJ, Atkinson G, Batterham AM. Inter-individual differences in weight change following exercise interventions: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2018;19(7):960-975. doi:10.1111/obr.12682
Gadbury GL, Iyer HK. Unit-treatment interaction and its practical consequences. Biometrics. 2000;56(3):882-885. doi:10.1111/j.0006-341X.2000.00882.x
Poulson RS, Gadbury GL, Allison DB. Treatment heterogeneity and individual qualitative interaction. Am Statistician. 2012;66(1):16-24. doi:10.1080/00031305.2012.671724
Gadbury GL, Iyer HK, Allison DB. Evaluating subject-treatment interaction when comparing two treatments. J Biopharm Stat. 2001;11(4):313-333. doi:10.1081/BIP-120008851
Cortés J, González JA, Medina MN, et al. Does evidence support the high expectations placed in precision medicine? A bibliographic review. F1000Research. 2019;7:30. doi:10.12688/f1000research.13490.4
Senn S. Controversies concerning randomization and additivity in clinical trials. Stat Med. 2004;23(24):3729-3753. doi:10.1002/sim.2074
Senn S. Added values: controversies concerning randomization and additivity in clinical trials. Stat Med. 2004;23(24):3729-3753. doi:10.1002/sim.2074
Albert JM, Gadbury GL, Mascha EJ. Assessing treatment effect heterogeneity in clinical trials with blocked binary outcomes. Biomet J: J Math Meth Biosci. 2005;47(5):662-673. doi:10.1002/bimj.200510157
Gadbury GL, Iyer HK, Albert JM. Individual treatment effects in randomized trials with binary outcomes. J Stat Planning Inference. 2004;121(2):163-174. doi:10.1016/S0378-3758(03)00115-0
Holland PW. Statistics and causal inference. J am Stat Assoc. 1986;81(396):945-960. doi:10.1080/01621459.1986.10478354
Fairchild AJ, MacKinnon DP. Using mediation and moderation analyses to enhance prevention research. In: Defining Prevention Science. Springer; 2014:537-555. doi:10.1007/978-1-4899-7424-2_23
Fairchild AJ, McQuillin SD. Evaluating mediation and moderation effects in school psychology: a presentation of methods and review of current practice. J Sch Psychol. 2010;48(1):53-84. doi:10.1016/j.jsp.2009.09.001
Nunes EV, Pavlicova M, Hu MC, et al. Baseline matters: the importance of covariation for baseline severity in the analysis of clinical trials. Am J Drug Alcohol Abuse. 2011;37(5):446-452. doi:10.3109/00952990.2011.596980
Marre M, van Gaal L, Usadel KH, Ball M, Whatmough I, Guitard C. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab. 2002;4(3):177-186. doi:10.1046/j.1463-1326.2002.00196.x
Kraemer HC, Frank E, Kupfer DJ. Moderators of treatment outcomes: clinical, research, and policy importance. Jama. 2006;296(10):1286-1289. doi:10.1001/jama.296.10.1286
Cohen J, Cohen P, West SG, Aiken LS. Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences. Routledge; 2013.
Aiken LS, West SG, Reno RR. Multiple Regression: Testing and Interpreting Interactions. Sage; 1991.
VanderWeele T, Knol M. A tutorial on interaction. Epidemiol Methods. 2014;3:33-72.
Knol MJ, VanderWeele TJ. Recommendations for presenting analyses of effect modification and interaction. Int J Epidemiol. 2012;41(2):514-520. doi:10.1093/ije/dyr218
Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. Vol. 3. Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008.
Rothman KJ, Greenland S, Walker AM. Concepts of interaction. Am J Epidemiol. 1980;112(4):467-470. doi:10.1093/oxfordjournals.aje.a113015
Crona K. Rank orders and signed interactions in evolutionary biology. Elife. 2020;9:e51004. doi:10.7554/eLife.51004
Widaman KF, Helm JL, Castro-Schilo L, Pluess M, Stallings MC, Belsky J. Distinguishing ordinal and disordinal interactions. Psychol Methods. 2012;17(4):615-622. doi:10.1037/a0030003
Angus DC, Chang C-CH. Heterogeneity of treatment effect: estimating how the effects of interventions vary across individuals. Jama. 2021;326(22):2312-2313. doi:10.1001/jama.2021.20552
Brown AW, Bohan Brown MM, Onken KL, Beitz DC. Short-term consumption of sucralose, a nonnutritive sweetener, is similar to water with regard to select markers of hunger signaling and short-term glucose homeostasis in women. Nutr Res. 2011;31(12):882-888. doi:10.1016/j.nutres.2011.10.004
Renjilian DA, Perri MG, Nezu AM, McKelvey WF, Shermer RL, Anton SD. Individual versus group therapy for obesity: effects of matching participants to their treatment preferences. J Consult Clin Psychol. 2001;69(4):717-721. doi:10.1037/0022-006X.69.4.717
Gardner CD, Trepanowski JF, del Gobbo LC, et al. Effect of low-fat vs low-carbohydrate diet on 12-month weight loss in overweight adults and the association with genotype pattern or insulin secretion: the DIETFITS randomized clinical trial. Jama. 2018;319(7):667-679. doi:10.1001/jama.2018.0245
Brown AW, Hang J, Dussault PH, Carr TP. Plant sterol and stanol substrate specificity of pancreatic cholesterol esterase. J Nutr Biochem. 2010;21(8):736-740. doi:10.1016/j.jnutbio.2009.04.008
Brown AW, Hang J, Dussault PH, Carr TP. Phytosterol ester constituents affect micellar cholesterol solubility in model bile. Lipids. 2010;45(9):855-862. doi:10.1007/s11745-010-3456-6
Allen PS, Brown AW, Brown MM, Hsu WH, Beitz DC. Taurine and vitamin E supplementations have minimal effects on body composition, hepatic lipids, and blood hormone and metabolite concentrations in healthy Sprague Dawley rats. Nutr Diet Suppl. 2015;7:77-85.
McClelland GH, Judd CM. Statistical Difficulties of Detecting Interactions and Moderator Effects. American Psychological Association; 1993:376-390.
Shieh G. Sample size determination for examining interaction effects in factorial designs under variance heterogeneity. Psychol Methods. 2018;23(1):113-124. doi:10.1037/met0000150
Rouder JN, Engelhardt CR, McCabe S, Morey RD. Model comparison in ANOVA. Psychon Bull Rev. 2016;23(6):1779-1786. doi:10.3758/s13423-016-1026-5
Senn SS. Cross-Over Trials in Clinical Research. Vol. 5. John Wiley & Sons; 2002. doi:10.1002/0470854596
Gewandter JS, McDermott MP, He H, et al. Demonstrating heterogeneity of treatment effects among patients: an overlooked but important step toward precision medicine. Clin Pharmacol Ther. 2019;106(1):204-210. doi:10.1002/cpt.1372
Ezzet F, Whitehead J. A random effects model for binary data from crossover clinical trials. J R Stat Soc Ser C Appl Stat. 1992;41(1):117-126. doi:10.2307/2347622
Gardiner JC, Luo Z, Roman LA. Fixed effects, random effects and GEE: what are the differences? Stat Med. 2009;28(2):221-239. doi:10.1002/sim.3478
McCulloch CE, Searle SR. Generalized, Linear, and Mixed Models. John Wiley & Sons; 2004.
Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. Bayesian data analysis. In: Hall CA, ed. Journal of the Royal Statistical Society Series A. Vol.178. Chapman and Hall; 2004.
Schmid CH, Brown EN. Bayesian hierarchical models. In: Methods in Enzymology. Elsevier; 2000:305-330. doi:10.1016/S0076-6879(00)21200-7
Huber AM, Tomlinson GA, Koren G, Feldman BM. Amitriptyline to relieve pain in juvenile idiopathic arthritis: a pilot study using Bayesian metaanalysis of multiple N-of-1 clinical trials. J Rheumatol. 2007;34(5):1125-1132.
Mitchell GK, Hardy JR, Nikles CJ, et al. The effect of methylphenidate on fatigue in advanced cancer: an aggregated n-of-1 trial. J Pain Symptom Manage. 2015;50(3):289-296. doi:10.1016/j.jpainsymman.2015.03.009
Nathan P, Tomlinson G, Dupuis LL, et al. A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design. Support Care Cancer. 2006;14(3):268-276. doi:10.1007/s00520-005-0875-7
Sung L, Tomlinson GA, Greenberg ML, et al. Serial controlled N-of-1 trials of topical vitamin E as prophylaxis for chemotherapy-induced oral mucositis in paediatric patients. Eur J Cancer. 2007;43(8):1269-1275. doi:10.1016/j.ejca.2007.02.001
Balaam L. A two-period design with t2 experimental units. Biometrics. 1968;24(1):61-73. doi:10.2307/2528460
Laird NM, Skinner J, Kenward M. An analysis of two-period crossover designs with carry-over effects. Stat Med. 1992;11(14-15):1967-1979. doi:10.1002/sim.4780111415
Candel M. Parallel, AA/BB, AB/BA and Balaam's design: efficient and maximin choices when testing the treatment effect in a mixed effects linear regression. Pharm Stat. 2012;11(2):97-106. doi:10.1002/pst.502
Mori J, Kano Y. A powerful test for Balaam's design. Pharm Stat. 2015;14(6):464-470. doi:10.1002/pst.1703
Loop MS, Frazier-Wood AC, Thomas AS, et al. Submitted for your consideration: potential advantages of a novel clinical trial design and initial patient reaction. Front Genet. 2012;3:145. doi:10.3389/fgene.2012.00145
Araujo A, Julious S, Senn S. Understanding variation in sets of N-of-1 trials. PLoS ONE. 2016;11(12):e0167167. doi:10.1371/journal.pone.0167167
Potter T, Vieira R, de Roos B. Perspective: application of N-of-1 methods in personalized nutrition research. Adv Nutr. 2021;12(3):579-589. doi:10.1093/advances/nmaa173
Friedman LM, Furberg CD, DeMets DL, et al. The randomization process. In: Friedman LM et al., eds. Fundamentals of Clinical Trials. Springer International Publishing; 2015:123-145. doi:10.1007/978-3-319-18539-2_6
Shadish WR. Experimental and Quasi-Experimental Designs for Generalized Causal Inference. Houghton Mifflin; 2001. doi:10.1016/B0-08-043076-7/00419-8
Brewin CR, Bradley C. Patient preferences and randomised clinical trials. BMJ. Br Med J. 1989;299(6694):313-315.
Long Q, Little RJ, Lin X. Causal inference in hybrid intervention trials involving treatment choice. J am Stat Assoc. 2008;103(482):474-484. doi:10.1198/016214507000000662
Marcus SM, Stuart EA, Wang P, Shadish WR, Steiner PM. Estimating the causal effect of randomization versus treatment preference in a doubly randomized preference trial. Psychol Methods. 2012;17(2):244-254. doi:10.1037/a0028031
King M, Nazareth I, Lampe F, et al. Impact of participant and physician intervention preferences on randomized trials: a systematic review. Jama. 2005;293(9):1089-1099. doi:10.1001/jama.293.9.1089
Torgerson DJ, Klaber-Moffett J, Russell IT. Patient preferences in randomised trials: threat or opportunity? J Health Serv Res Policy. 1996;1(4):194-197. doi:10.1177/135581969600100403
Zelen M. Randomized consent designs for clinical trials: an update. Stat Med. 1990;9(6):645-656. doi:10.1002/sim.4780090611
Torgerson DJ, Roland M. What is Zelen's design? BMJ (Clin Res Ed). 1998;316(7131):606. doi:10.1136/bmj.316.7131.606
Heo M, Meissner P, Litwin AH, et al. Preference option randomized design (PORD) for comparative effectiveness research: statistical power for testing comparative effect, preference effect, selection effect, intent-to-treat effect, and overall effect. Stat Methods Med Res. 2017;28(2):626-640. doi:10.1177/0962280217734584
Rucker G. A two-stage trial design for testing treatment, self-selection and treatment preference effects. Stat Med. 1989;8(4):477-485. doi:10.1002/sim.4780080411
Preference Collaborative Review, G. Patients' preferences within randomised trials: systematic review and patient level meta-analysis. BMJ (Clin Res Ed). 2008;337(oct31 1):a1864. doi:10.1136/bmj.a1864
Yancy WS Jr, Coffman CJ, Geiselman PJ, et al. Considering patient diet preference to optimize weight loss: design considerations of a randomized trial investigating the impact of choice. Contemp Clin Trials. 2013;35(1):106-116. doi:10.1016/j.cct.2013.03.002
Yancy WS Jr, Mayer SB, Coffman CJ, et al. Effect of allowing choice of diet on weight loss: a randomized trial. Ann Intern Med. 2015;162(12):805-814. doi:10.7326/M14-2358
Burke LE, Warziski M, Styn MA, Music E, Hudson AG, Sereika SM. A randomized clinical trial of a standard versus vegetarian diet for weight loss: the impact of treatment preference. Int J Obes (Lond). 2008;32(1):166-176. doi:10.1038/sj.ijo.0803706
US Food and Drug Administration. Guidance for Industry: Frequently Asked Questions About GRAS. 2004 [cited 2020 August 12]; Available from: http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm061846.htm
Elliman NA, Ash J, Green MW. Pre-existent expectancy effects in the relationship between caffeine and performance. Appetite. 2010;55(2):355-358. doi:10.1016/j.appet.2010.03.016
Kelemen WL, Kaighobadi F. Expectancy and pharmacology influence the subjective effects of nicotine in a balanced-placebo design. Exp Clin Psychopharmacol. 2007;15(1):93-101. doi:10.1037/1064-1297.15.1.93
Waring DR. The antidepressant debate and the balanced placebo trial design: an ethical analysis. Int J Law Psychiatry. 2008;31(6):453-462. doi:10.1016/j.ijlp.2008.09.001
George BJ, Li P, Lieberman HR, et al. Randomization to randomization probability: estimating treatment effects under actual conditions of use. Psychol Methods. 2018;23(2):337-350. doi:10.1037/met0000138
Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979;16(3):183-187. doi:10.1007/BF00562059
Mahgoub A, Dring LG, Idle JR, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet. 1977;310(8038):584-586. doi:10.1016/S0140-6736(77)91430-1
McDonnell AM, Dang CH. Basic review of the cytochrome p450 system. J Adv Pract Oncol. 2013;4(4):263-268. doi:10.6004/jadpro.2013.4.4.7
Jurado-Escobar R, Perkins JR, García-Martín E, et al. Update on the genetic basis of drug hypersensitivity reactions. J Investig Allergol Clin Immunol. 2017;27(6):336-345. doi:10.18176/jiaci.0199
Prat A, Ellis MJ, Perou CM. Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol. 2012;9(1):48-57. doi:10.1038/nrclinonc.2011.178
Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci. 2003;100(14):8418-8423. doi:10.1073/pnas.0932692100
Liu MC, Pitcher BN, Mardis ER, et al. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline-and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). NPJ Breast Cancer. 2016;2(1):15023. doi:10.1038/npjbcancer.2015.23
Buniello A, MacArthur JAL, Cerezo M, et al. The NHGRI-EBI GWAS catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 2019;47(D1):D1005-D1012. doi:10.1093/nar/gky1120
Giacomini KM, Yee SW, Mushiroda T, Weinshilboum RM, Ratain MJ, Kubo M. Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. Nat Rev Drug Discov. 2017;16(1):70. doi:10.1038/nrd.2016.234
MacLean PS, Rothman AJ, Nicastro HL, et al. The accumulating data to optimally predict obesity treatment (ADOPT) core measures project: rationale and approach. Obesity. 2018;26(Suppl 2):S6-s15. doi:10.1002/oby.22154
Bray MS, Loos RJF, McCaffery JM, et al. NIH working group report-using genomic information to guide weight management: from universal to precision treatment. Obesity. 2016;24(1):14-22. doi:10.1002/oby.21381
Scott RA. Unraveling the role for genetics in enabling precision prescription for weight loss-scaling up for success. Obesity. 2016;24(1):12-13. doi:10.1002/oby.21380
Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet. 2018;19(9):581-590. doi:10.1038/s41576-018-0018-x
de los Campos G, Gianola D, Allison DB. Predicting genetic predisposition in humans: the promise of whole-genome markers. Nat Rev Genet. 2010;11(12):880-886. doi:10.1038/nrg2898
Gilbert D, Lyngdoh T. Stumbling on Happiness. SAGE Publications Sage India; 2015.
Rikke BA, Battaglia ME, Allison DB, Johnson TE. Murine weight loss exhibits significant genetic variation during dietary restriction. Physiol Genomics. 2006;27(2):122-130. doi:10.1152/physiolgenomics.00068.2006
Bomberg EM, Ryder JR, Brundage RC, et al. Precision medicine in adult and pediatric obesity: a clinical perspective. Ther Adv Endocrinol Metab. 2019;10:2042018819863022.
Beavers DP, Hsieh KL, Kitzman DW, et al. Estimating heterogeneity of physical function treatment response to caloric restriction among older adults with obesity. PLoS ONE. 2022;17(5):e0267779. doi:10.1371/journal.pone.0267779
Volkmann C, Volkmann A, Müller CA. On the treatment effect heterogeneity of antidepressants in major depression: a Bayesian meta-analysis and simulation study. PLoS ONE. 2020;15(11):e0241497. doi:10.1371/journal.pone.0241497
Mattson MP. Genes and behavior interact to determine mortality in mice when food is scarce and competition fierce. Aging Cell. 2010;9(3):448-449. doi:10.1111/j.1474-9726.2010.00561.x
Speakman JR, Loos RJF, O'Rahilly S, Hirschhorn JN, Allison DB. GWAS for BMI: a treasure trove of fundamental insights into the genetic basis of obesity. Int J Obes (Lond). 2018;42(8):1524-1531. doi:10.1038/s41366-018-0147-5
El-Sayed Moustafa JS, Froguel P. From obesity genetics to the future of personalized obesity therapy. Nature reviews. Endocrinology. 2013;9(7):402-413. doi:10.1038/nrendo.2013.57
Wang J, García-Bailo B, Nielsen DE, el-Sohemy A. ABO genotype, ‘blood-type’ diet and cardiometabolic risk factors. PLoS ONE. 2014;9(1):e84749. doi:10.1371/journal.pone.0084749
Zhang X, Qi Q, Zhang C, et al. FTO genotype and 2-year change in body composition and fat distribution in response to weight-loss diets: the POUNDS LOST trial. Diabetes. 2012;61(11):3005-3011. doi:10.2337/db11-1799
Bayer S, Winkler V, Hauner H, Holzapfel C. Associations between genotype-diet interactions and weight loss-a systematic review. Nutrients. 2020;12(9):2891. doi:10.3390/nu12092891
Wong JM, Yu S, Ma C, et al. Stimulated insulin secretion predicts changes in body composition following weight loss in adults with high BMI. J Nutr. 2022;152(3):655-662. doi:10.1093/jn/nxab315
Cefalu WT, Bray GA, Home PD, et al. Advances in the science, treatment, and prevention of the disease of obesity: reflections from an editors' expert forum. Diabetes Care. 2015;38(8):1567-1582. doi:10.2337/dc15-1081
Popper, K., The Open Universe. 1982.
Goulding R, Dawes D, Price M, Wilkie S, Dawes M. Genotype-guided drug prescribing: a systematic review and meta-analysis of randomized control trials. Br J Clin Pharmacol. 2015;80(4):868-877. doi:10.1111/bcp.12475